Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT06859190Phase 3Recruiting
Phase 3, randomised, open-label trial (2 arms), sponsored by Qinghai Red Cross Hospital. Primary endpoint: Insomnia Severity Index at 20 weeks. Started Mar 2025; status: recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT06859190.